Zacks Research Issues Positive Forecast for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Research analysts at Zacks Research boosted their Q3 2025 earnings per share (EPS) estimates for shares of Zoetis in a note issued to investors on Monday, May 26th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $1.67 per share for the quarter, up from their prior forecast of $1.62. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q4 2025 earnings at $1.54 EPS, FY2025 earnings at $6.28 EPS, Q1 2026 earnings at $1.58 EPS, Q2 2026 earnings at $1.70 EPS, Q3 2026 earnings at $1.73 EPS, Q4 2026 earnings at $1.75 EPS and FY2026 earnings at $6.76 EPS.

ZTS has been the subject of a number of other reports. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Piper Sandler boosted their price objective on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, May 12th. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. UBS Group cut their price objective on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Finally, Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $212.75.

Zoetis Trading Up 0.9%

Zoetis stock opened at $168.71 on Thursday. The business has a 50-day simple moving average of $156.80 and a two-hundred day simple moving average of $164.59. The company has a market cap of $75.11 billion, a P/E ratio of 30.84, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 EPS.

Institutional Trading of Zoetis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Nova Wealth Management Inc. purchased a new stake in Zoetis during the 1st quarter valued at $25,000. Strs Ohio purchased a new stake in Zoetis during the 1st quarter valued at $22,891,000. GK Wealth Management LLC raised its holdings in Zoetis by 22.7% during the 1st quarter. GK Wealth Management LLC now owns 2,373 shares of the company’s stock valued at $391,000 after buying an additional 439 shares during the period. Ellsworth Advisors LLC raised its holdings in Zoetis by 11.0% during the 1st quarter. Ellsworth Advisors LLC now owns 10,225 shares of the company’s stock valued at $1,684,000 after buying an additional 1,012 shares during the period. Finally, Jacobi Capital Management LLC raised its holdings in Zoetis by 5.7% during the 1st quarter. Jacobi Capital Management LLC now owns 9,490 shares of the company’s stock valued at $1,563,000 after buying an additional 512 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This represents a 2.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.18% of the company’s stock.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.19%. Zoetis’s dividend payout ratio is presently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.